Upcoming Event: Biologics Manufacturing Asia 2020
11/21/2019
Event: Biologics
Manufacturing Asia 2020
Dates:
February 18 – 19,
2020
Venue: Suntec
Convention Centre Singapore, Singapore
Weblink: www.imapac.com/en/business_conferences/biologics-manufacturing-asia/?popup#agenda
Contact:
Ms. Aisyah Atiqah
Tel: +65 3109 0158
Email: aisyah.atiqah@imapac.com
The biologics industry in Asia- Pacific is estimated
to be the fastest growing market in the world. For instance, Asia- Pacific
accounts for 30-40% of the global biosimilars market. The key drivers
driving the growth of the biologics industry in Asia are competitive
manufacturing costs, the increase in of high-skilled workers, new- cell culture
techniques, fast-track flexible GMP facilities equipped with disposables,
attempts for integrated continuous manufacturing, combining modular facilities,
single-use and other advances in the downstream processing of biologics.
However, the factors hindering the growth of the biopharmaceutical industry
mainly are from the bioprocessing side including high-manufacturing
complexities, expensive purification processes and other challenges across the
bioprocessing value chain.
To facilitate brainstorming, strategy-generating discussions on the
aforementioned key aspects of the biologics industry, IMAPAC is bringing to you
2 focus areas:
Bio-Manufacturing and Cell Therapy
Manufacturing and Supply Chain as part of Asia's biggest, most focussed
annual bioprocessing conference, the 7th Annual Biologics Manufacturing Asia 2020!
In 2020, 500+ bio manufacturing stakeholders
from BIG Pharma, Biopharma, Contract Manufacturing Organisations, Academic
& Research Institutes, Regulatory Authorities, and Solution Providers
across Singapore, South Korea, Taiwan, Japan, Australia, India, South East
Asia, Indo China, and China will convene to discover, discuss and debate
on the best manufacturing practices to make better biologic drugs cheaper and
faster!
The convention aims to provide a neutral platform to address the challenges
faced in this sector including:
-
Understanding and evaluating in-line process analytical testing approaches for process controls and automation for semi-continuous manufacturing, reduced waste and downtime with increased profitability.
- The necessity for unit operations to be connected to facilitate a continuous or
semi-continuous product flow and consequently need to be controlled simultaneously.
- The need to take advantage of real-time monitoring data of cell culture
behaviour and product characteristics during development for enactment of a
robust compliant process control system.
- Development of robust processes to suit evolving bio manufacturing needs.
- Optimization of downstream purification for highly complex molecules.
- Designing and automating quality control during scale-up and process
change.
- Cost-Benefit analysis between the use of disposables vs hard-piped steel
containers vs hybrid facilities.Perceived barriers to switch over from batch to continuous manufacturing and
the future prospects and challenges faced by companies planning for the
paradigm shift.
Join us in 2020 in Singapore: the
biomanufacturing hub of Asia, strong government support, easy access from all
Asian countries, technological leadership and home to top biopharmaceutical
companies developing smart manufacturing facilities for the production of
biologic drugs, to convene on the best manufacturing practices in order to have
access to faster, cheaper and better biologic drugs!